187 related articles for article (PubMed ID: 28273450)
21. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
22. An immune-active tumor microenvironment favors clinical response to ipilimumab.
Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
[TBL] [Abstract][Full Text] [Related]
23. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
24. A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis.
Claps G; Cheli Y; Zhang T; Scortegagna M; Lau E; Kim H; Qi J; Li JL; James B; Dzung A; Levesque MP; Dummer R; Hayward NK; Bosenberg M; Brown KM; Ronai ZA
Cell Rep; 2016 May; 15(9):1884-92. PubMed ID: 27210757
[TBL] [Abstract][Full Text] [Related]
25. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
[TBL] [Abstract][Full Text] [Related]
26. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
27. Re: Determinants of BRAF mutations in primary melanomas.
Purdue MP
J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
[No Abstract] [Full Text] [Related]
28. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
29. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
[TBL] [Abstract][Full Text] [Related]
30. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
31. Distinctive clinical and dermoscopic features of BRAF V600K mutated melanomas.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Br J Dermatol; 2015; 172(5):1438-40. PubMed ID: 25323827
[No Abstract] [Full Text] [Related]
32. Cells to Surgery Quiz: October 2015.
Aldahan AS; Mlacker S; Shah VV; Samarkandy S; Alsaidan M; Nouri K
J Invest Dermatol; 2015 Oct; 135(10):e18. PubMed ID: 26358388
[No Abstract] [Full Text] [Related]
33. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
[TBL] [Abstract][Full Text] [Related]
34. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
Whipple CA; Boni A; Fisher JL; Hampton TH; Tsongalis GJ; Mellinger DL; Yan S; Tafe LJ; Brinckerhoff CE; Turk MJ; Mullins DW; Fadul CE; Ernstoff MS
Melanoma Res; 2016 Jun; 26(3):223-35. PubMed ID: 26974965
[TBL] [Abstract][Full Text] [Related]
35. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
36. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
[TBL] [Abstract][Full Text] [Related]
37. Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.
Brocard A; Knol AC; Bossard C; Denis MG; Quéreux G; Saint-Jean M; Peuvrel L; Khammari A; Blancho G; Dantal J; Dréno B
Acta Derm Venereol; 2017 Apr; 97(4):483-488. PubMed ID: 27868139
[TBL] [Abstract][Full Text] [Related]
38. Endothelin-1 in the tumor microenvironment correlates with melanoma invasion.
Chiriboga L; Meehan S; Osman I; Glick M; de la Cruz G; Howell BS; Friedman-Jiménez G; Schneider RJ; Jamal S
Melanoma Res; 2016 Jun; 26(3):236-44. PubMed ID: 26825037
[TBL] [Abstract][Full Text] [Related]
39. Modulation of activated leukocyte cell adhesion molecule-mediated invasion triggers an innate immune gene response in melanoma.
van Kilsdonk JW; Takahashi N; Weidle U; Burtscher H; Jarry J; Daha MR; Swart GW; van Kempen LC
J Invest Dermatol; 2012 May; 132(5):1462-70. PubMed ID: 22318386
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
